Get informed when a big investor buys or sells
+ FollowOvervalued by 166.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $445.86 Million |
|---|---|
| Enterprise Value | $411.57 Million |
| Earnings per Share | $-0.03 |
| Beta | 1.91 |
| Outstanding Shares | 171,483,903 |
| P/E Ratio | -25.44 |
|---|---|
| PEG | -79.17 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 68.1 |
| Enterprise Value to EBIT | -24 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity ass...